Delivery Order SPE2DB24D8002-SPE2DB25FJNPU

Award Date 4/25/25
Potential Completion Date 4/28/25
Potential Value $3.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $11,879.56, is for the delivery of Dupixent 300 mg/2 ml syringes to support U.S. Armed Forces medical operations. The contract has a firm fixed price pricing type and a performance period through January 23, 2024. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of Dupixent 300 mg/2 ml syringes. The contract is a firm fixed-price delivery order with a ceiling value of $3,056.09 and a period of performance through February 12, 2025. Dakota Drug, Inc. is also the prime contractor on a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA as part of the ECAT Generation V...
This federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, was issued by the Defense Logistics Agency (DLA) and has a ceiling value of $6,356.82. The contract is a delivery order with a firm fixed price and an ultimate completion date of March 12, 2025. The contract is for the delivery of Dupixent 300 mg/2 ml syringes to support U.S. Armed Forces medical operations. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $7,091.73 to Dakota Drug, Inc., a self-certified small disadvantaged business located in Anoka, Minnesota. This contract, with a performance period ending on March 4, 2024, is for the delivery of Dupixent 300 mg/2 ml syringes. This award is part of a larger Indefinite Delivery Contract (IDC), identified as SPE2DB24D8001, which allows Dakota Drug, Inc. to provide a wide range of pharmaceutical...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $13,666.77, is for the delivery of Dupixent 300 mg/2 ml syringes to support U.S. Armed Forces medical operations. The contract is a firm-fixed-price, unrestricted (no set-aside) contract with a performance period ending on April 29, 2024. Dakota Drug, Inc. is a key supplier of pharmaceutical products, medical...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business. The $1,867.25 firm-fixed-price contract is for the delivery of a pharmaceutical product, Dupixent 300 mg/2 ml syringe, with a completion date of December 6, 2023. Dakota Drug, Inc. is a key supplier of pharmaceutical products, medical supplies, and healthcare equipment to the U.S. Department of Defense. The company holds a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business located in Anoka, Minnesota. The order, valued at $3,004.85, is for the supply of Dupixent 300 mg/2 ml syringes. The contract is a firm fixed-price delivery order that runs through May 12, 2025. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, as part of the DLA Troop Support Medical's ECAT...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of Dupixent 300 mg/2 ml syringes. The contract has a firm fixed price of $3,179.33 and a period of performance through February 26, 2025. Dakota Drug, Inc. holds a significant Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, under the DLA Troop Support Medical's ECAT Generation V Program. This IDC allows...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $23,237.03, is for the delivery of Dupixent 300 mg/2 ml syringes. Dakota Drug, Inc. is a key supplier of pharmaceutical products, medical supplies, and healthcare equipment to the U.S. federal government, particularly the Department of Defense. The company holds a significant single-award Indefinite Delivery...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $7,274.15 firm fixed-price delivery order is for the pharmaceutical product DUPIXENT 300 MG/2 ML SYRINGE 2ML, with a period of performance through February 1, 2024. Dakota Drug, Inc. holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, as part of the ECAT Generation V Program, which allows the...
  • SPE2DB24D8002
    Indefinite Delivery Contract
  • SPE2DB24D8002-SPE2DB25FJNPU
    Delivery Order

This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a small disadvantaged business located in Anoka, Minnesota. The contract is for the delivery of pharmaceutical products, specifically Dupixent 300 mg/2 ml syringes, to support U.S. Armed Forces medical operations. The contract has a ceiling value of $3,734.50 and a performance period ending on April 28, 2025.

Dakota Drug, Inc. also holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, which allows the company to provide a comprehensive range of pharmaceutical products, medical supplies, and healthcare equipment to the military. This IDC is part of the DLA Troop Support Medical's ECAT Generation V Program and runs through December 31, 2025. The contract was not set aside for any specific business category.

Generated 7/25/25, 11:10 AM